Bard ends deal with drugs-for-devices firm Angiotech:
This article was originally published in Clinica
Executive Summary
CR Bard and Angiotech Pharmaceuticals have, "by mutual agreement", ended a collaboration to develop a paclitaxel-loaded "vascular wrap". Vancouver, Canada-based Angiotech said the five-year partnership was ended because the device firm did not usually invest in such long-term, expensive programmes. Having been responsible for development of the product, which is designed to treat stenosis in peripheral vascular surgery, Angiotech says it will be able to continue the programme independently with no delays or disruptions. Angiotech's most high-profile drug-device partnership to date is with Boston Scientific, which is hoping to launch its paclitaxel-coated stent in the US next year.
You may also be interested in...
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.